SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Coin Magi

Coin Magi ($XMG) is facing heavy selling pressure and a confirmed downtrend, leading to negative sentiment within the community. Discussions revolve around price bleeding, failed recovery attempts, and bearish chart patterns. Some users highlight a recent hard fork and platform update, while others express concerns about a potential market downturn.

this coin is scarce

SCARCE CRYPTO is gaining attention as the community emphasizes its limited availability and potential value. Traders are monitoring its chart patterns and consistent support levels, while also debating the legitimacy of the coin and its scarcity compared to other cryptocurrencies like Bitcoin. The community buzz suggests anticipation for a potential breakout, with many encouraging others to get in early.

Solana Street Bets is not just a memecoin; it's a symbol of creativity, humor, and the power of a united community. Inspired by the infamous /wallstreetbets subreddit. Solana Street Bets is here to put respect on the Wall St originated memes in the industry. Solana Street Bets is a decentralized Solana meme coin inspired by the infamous /wallstreetbets subreddit.

SatoshiStreetBets

SatoshiStreetBets (SSB) is gaining traction, with community members highlighting its disciplined chart patterns and healthy retraces. Discussions revolve around the token's structure and a focus on methodical pacing, with many expressing conviction and patience during its accumulation phase.  The community also focuses on a clean chart, steady volume, and the importance of process over prediction.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending amidst discussions around potential price drops and strong support levels, with some traders eyeing it for short-term gains. Community members are debating its long-term potential versus meme coin opportunities on the Solana blockchain, as well as the broader impact of Bitcoin's price action on Solana's movements. The launch of VanEck's Solana ETF is also driving interest, despite concerns about the token's recent performance relative to Bitcoin and Ethereum.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings ($RCAT) is trending amid discussions about revised guidance and its impact on the company's timeline, with debates around CEO performance and concerns about contract delays.  The community is weighing the company's potential in the drone sector against its financial performance and leadership, with some drawing comparisons to competitors like Ondas ($ONDS). Bearish sentiment is building while long-term bulls defend their positions.

About Mistery On Cro $MERY was born with the idea of being a meme coin on Cronos chain during the exploding 2024 meme coin season. The founder is David Bui, a well-known and seasoned #crofam $CRO investor on Cryptocom products and a big -well respected- personality on X. David minted “Mistery On CRO” on Cronos blockchain with the purpose of making this chain much better, more popular and specially more fun, but aside from serving as a mere “meme”, $MERY has the ultimate goal of also being a utility token that the founder and the team behind will push to bring many benefits to loyal hodlers. Launched in 27/3/2024 at Sydney, Australia, local time 21h00, the 690,000 $CRO presale sold out within 2 hours. The founder burned the LP to a dead wallet and the contract ownership was renounced. $MERY during its first week of launch got instant traction from the OG #crofam community who jumped in and secured bags. We are now a thriving community that will help nurturing and growing the project by sharing with more and more Web3 users.

Mistery

$MERY is trending as a 'native community meme' coin on crypto.com/us, with community chatter focusing on the exchange's considerable ownership and locked developer coins as possible 'rug-proof' qualities. Discussions also highlight its connection to $CRO and the active Telegram game, sparking optimism for further price appreciation.

Pinterest, Inc. engages in the operation of a pinboard-style photo-sharing website. It allows users to create and manage theme-based image collections such as events, interests, and hobbies. The company was founded by Benjamin Silbermann, Paul C. Sciarra, and Evan Sharp in October 2008 and is headquartered in San Francisco, CA.

Pinterest Inc - Ordinary Shares - Class A

Pinterest Inc

PINS is trending amid discussions about its valuation and potential catalysts, with some suggesting it's undervalued while others point to mixed earnings results and bearish sentiment. Community members are actively debating potential buyback programs, AI partnerships, and the possibility of a buyout, contributing to the heightened interest in the stock. Technical analysis indicates an oversold condition, but moving averages suggest a bearish outlook, leading to varied trading strategies.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman Sachs ($GS) is trending as regulatory changes could boost bank profits, with discussions focusing on potential lending power increases. Community analysis suggests a slight bullish bias based on moving averages, though some anticipate a pullback. Additionally, GS's strategic moves into private equity, including acquisitions and fundraising, are generating buzz around its growth potential.

L3Harris Technologies, Inc. engages in the provision of defense and commercial technologies across the air, land, sea, space, and cyber domains. It operates through the following segments: Space and Airborne Systems, Integrated Mission Systems, Communication Systems, and Aerojet Rocketdyne. The Space and Airborne Systems segment provides full mission solutions as a prime and subsystem integrator in the space, airborne and cyber domains. The Integrated Mission Systems segment focuses on the differentiated mission capabilities and prime systems integration for the air, land and sea domains. The Communication Systems segment enables warfighters across all domains with solutions critical to mission success even in the most contested environments. The Aerojet Rocketdyne segment includes propulsion, power and armament products and systems to U.S. government, including the DoD, National Aeronautics and Space Administration (“NASA”) and major aerospace and defense prime contractors. The company was founded in 1890 and is headquartered in Melbourne, FL.

L3Harris Technologies Inc

LHX is trending due to a mix of technical analysis indicating range-bound trading and call options activity suggesting potential upside, with traders eyeing potential profit from call contracts. Positive industry outlook as well, which is fueled by geopolitical tensions and strategic contracts is driving interest, while analysts adjust price targets. Community discussions revolve around entry points and potential ROI, considering factors like moving averages and RSI.

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment focuses on Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck in 2013 and is headquartered in San Francisco, CA.

Twist Bioscience Corp

TWST is trending amid discussions around its Q4 earnings, which beat revenue estimates but missed on EPS. The community is focused on the company's path to profitability and gross margin improvements, with some analysts raising price targets while others remain cautious. Options traders are active, with both bullish call buying and bearish put buying strategies being highlighted.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Day One Biopharmaceuticals Sees Unusually Large Options Volume (NASDAQ:DAWN)

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) was the recipient of unusually large options trading on Thursday. Stock investors purchased 3,055 call options on the stock. This is...

Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down - Here's Why

Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap Down - Time to Sell...

<ul class="summary-bullets"><li>Mersana surged even as multiple firms downgraded the stock following Day One’s acquisition agreement.</li><li>Analysts said competing bids are unlikely and noted Day One’s offer reflects confidence in Mersana’s assets.</li><li>Retail traders called the deal a bargain for Day One and highlighted Mersana’s broader pipeline value.</li></ul>Mersana Therapeutics logged its strongest trading session on record on Thursday, soaring even as a long list of Wall Street firms downgraded the stock after Day One Biopharmaceuticals agreed to acquire the company in a deal that could be worth up to $285 million.Day One Biopharmaceuticals closed down 14% on Thursday, while Mersana Therapeutics finished the session up 209%.<h2 class="st-heading-2">Analysts Weigh In On Day One’s Bid</h2>William Blair downgraded Mersana to ‘Market Perform’ from ‘Outperform’, saying it views it as unlikely that another bidder will emerge.Guggenheim cut its rating to ‘Neutral’ from ‘Buy’, while LifeSci Capital shifted its view to ‘Market Perform’ from ‘Outperform.’ Leerink moved the stock to ‘Market Perform’ from ‘Outperform’ and set a $29 price target. Truist downgraded Mersana to ‘Hold’ from ‘Buy’ and lowered its target to $30.75 from $36, saying it believes the deal will go through and estimating the CVR’s value at $5.75. BTIG lowered its rating to ‘Neutral’ from ‘Buy’, and Wedbush also cut the stock to ‘Neutral’ from ‘Outperform.’Oppenheimer said Day One paying up to $285 million for Mersana “is interesting.” The firm noted the acquisition “wasn't on the short list,” and said management had been “talking down PTK7,” and questioned whether Emi-Le may be positioned as its replacement. Oppenheimer added that Day One could have obtained a comparable asset from China at a lower cost and said the offer suggests management is “seeing something in Emi-Le.” The firm reiterated a ‘Perform’ rating on Day One.<h2 class="st-heading-2">Deal Terms</h2>Under the merger agreement, Day One will launch a tender offer within 10 business days of Nov. 12. The deal requires that a majority of Mersana’s shares be tendered for the transaction to proceed, after which any remaining shares would be acquired in a follow-on merger for the same consideration. Once completed, Mersana would become a wholly owned subsidiary of Day One, and its stock would be delisted.&nbsp;The agreement received unanimous board approval, and holders representing about 8.5% of outstanding shares, including executives, directors, and Bain Capital Life Sciences affiliates, have signed support agreements to tender their shares.<h2 class="st-heading-2">Legal Review</h2>Separately, law firm Ademi &amp; Fruchter said it is reviewing the deal for potential breaches of fiduciary duty, citing insider benefits, deal protection,s and limits on competing offers.<h2 class="st-heading-2">Stocktwits Traders Flag ‘Cheap’ Valuations</h2>On Stocktwits, retail sentiment for both Mersana and Day One was ‘extremely bullish’ amid ‘extremely high’ message volume.One user said, “If they were able to buy Mersana Therapeutics ($MRSN), they could easily buy $CHRS; I'm sure many companies are interested, it's very cheap.”<stembedurl>https://stocktwits.com/Sarandon/message/636088418</stembedurl>Another user argued that Day One is getting what they called “a very good bargain” in the acquisition, saying the company is “effectively getting the entire pipeline of Mersana for about $40 million” and adding, “I am buying the stock.”<stembedurl>https://stocktwits.com/Itinerant/message/636101103</stembedurl>A third user noted that while many investors had expected Day One to be a buyout target, in this deal the company instead acted as “Apex predator,” adding that it would be “interesting to watch further manifestations in this new constitution.”<stembedurl>https://stocktwits.com/GeniusLoci/message/636078018</stembedurl><a href="https://stocktwits.com/symbol/MRSN">Mersana’s stock</a> has more than tripled so far in 2025, while&nbsp;<a href="https://stocktwits.com/symbol/DAWN">Day One’s stock</a> has climbed 35% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mersana’s stock (MRSN) has more than tripled so far in 2025, while Day One’s stock (DAWN) has climbed 35% over the same period. (Photo credit: Getty Images)

Mersana Therapeutics Stock Explodes Over 200% To Notch Best Day Ever As $285M Buyout Trumps Analyst Downgrades: Retail Cheers ‘Very Good Bargain’

Mersana surged even as multiple firms downgraded the stock following Day One’s acquisition agreement.

Equity

Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout

Day One Biopharmaceuticals plans to acquire Mersana Therapeutics in a deal worth up to $285 million to expand its cancer drug portfolio.read more...

Mersana Therapeutics To Be Acquired By Day One Biopharmaceuticals For Up To $285 Mln

(RTTNews) - Mersana Therapeutics, Inc. (MRSN), a biopharmaceutical company, Thursday, announced that it has entered a definitive agreement to be acquired by Day One Biopharmaceuticals through a...

<ul class="summary-bullets"><li>Day One will purchase Mersana for a total consideration of up to $55.25 per share.&nbsp;</li><li>The transaction is expected to close by the end of January 2026, and Day One expects to finance it with existing cash resources.&nbsp;</li><li>The acquisition will add antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le) to Day One’s cancer portfolio.</li></ul>Day One Biopharmaceuticals, Inc. (DAWN) said on Thursday that it has signed a definitive merger agreement to acquire Mersana Therapeutics (MRSN) for up to $285 million to expand its oncology portfolio.Brisbane-based Day One will commence a tender offer to acquire all of the outstanding shares of Mersana common stock for $25 per share in cash at closing, in addition to a contingent value right that allows holders to receive up to an aggregate of $30.25 per CVR upon the completion of certain milestones for a total consideration of up to $55.25 per share.The upfront purchase price of $25 alone represents a premium of 182% from Mersana’s closing price on Wednesday. The transaction is expected to close by the end of January 2026, and Day One <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/13/3187097/0/en/Day-One-to-Acquire-Mersana-Therapeutics-to-Advance-Mission-to-Bring-New-Medicines-to-People-of-All-Ages-with-Life-Threatening-Diseases.html">expects</a> to finance it with existing cash resources.<a href="https://stocktwits.com/symbol/MRSN">MRSN shares</a> traded 200% higher in the pre-market session at the time of writing while <a href="https://stocktwits.com/symbol/DAWN">DAWN shares</a> dropped 12%.<h2 class="st-heading-2">Expanding Its Oncology Portfolio</h2>The acquisition will add antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le) to Day One’s cancer portfolio. Emi-Le has demonstrated early anti-tumor activity in an ongoing early-stage study for an aggressive cancer called adenoid cystic carcinoma type-1.Day One believes that Emi-Le is well-positioned for potential rapid development and commercialization and expects its financial profile to aid the development of it through potential approval with no additional financing.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around MRSN jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.MRSN stock is down by 75% this year and by 87% over the past 12 months. Meanwhile, DAWN stock has lost 18% this year.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/ford-gears-up-for-wider-bluecruise-rollout-across-europe-in-2026/cLP9TrNRE3g">Ford Gears Up For Wider BlueCruise Rollout Across Europe In 2026</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal

The upfront purchase price of $25 alone represents a premium of 182% from Mersana’s closing price on Wednesday.

Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

JPMorgan Chase & Co. lifted their target price on shares of Day One Biopharmaceuticals from $26.00 to $27.00 and gave the company an "overweight" rating in a research report on Friday...

Day One Biopharmaceuticals (NASDAQ:DAWN) Trading 8.5% Higher - Here's Why

Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Up 8.5% - Still a Buy...

Equities Analysts Issue Forecasts for DAWN FY2025 Earnings

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - HC Wainwright raised their FY2025 earnings per share estimates for Day One Biopharmaceuticals in a report released on Wednesday...

What is Wedbush's Estimate for DAWN FY2025 Earnings?

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Equities research analysts at Wedbush increased their FY2025 earnings per share (EPS) estimates for shares of Day One Biopharmaceuticals...

Day One Biopharmaceuticals, Inc. operates as a holding company. The firm, through its subsidiary, develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel C. Blackman in November 2018 and is headquartered in Brisbane, CA.

Day One Biopharmaceuticals Inc

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.19	--	--	N/A
Q3 '25	-$0.30	-$0.19	36.00%	BEAT
Q2 '25	-$0.36	-$0.29	18.66%	BEAT
Q1 '25	-$0.44	-$0.35	20.07%	BEAT
Q4 '24	-$0.36	-$0.63	-73.81%	MISSED

DAWN
Day One Biopharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest DAWN News

DAWNDay One Biopharmaceuticals Inc